Genmab — April 2021
-
Amivantamab revenue 378M$ i 2029, vinder på færre bivirkninger https://www.clinicaltrialsarena.com/comment/janssens-amivantamab-has-competitive-edge-over-spectrums-and-takedas-exon-20-mutation-directed-tkis-in-nsclc/
-
Thx for link bongobob - according to the article, effect is higher and safety better - but sales lower and slower...
-
Havde man ikke traded Genmab aktien det sidste år, så har det været døde penge siden maj 2020. Der er godt nok beskeden netto-købsinteresse i den.
-
-
Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab
https://pharmaphorum.com/views-and-analysis/jan-van-de-winkel-building-europes-biotech-powerhouse-at-genmab/ -
and from that - Genmab could spin out autoimmune disease unit, says CEO https://pharmaphorum.com/news/genmab-could-spin-out-autoimmune-disease-unit-says-ceo-goes-with-feature/
-
Exciting stuff EL - good to hear there are no plans to build an “autoimmune” organization
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind